Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Dr. Leighl continued her presentation on "Highlights in Lung Cancer, 2012" with a discussion of the challenges that many patients with squamous NSCLC face, typically not having a cancer with a "driver mutation" like an EGFR mutation or an ALK rearrangement. However, she notes that several new targets that may be especially relevant for patients with squamous NSCLC are becoming the subject of growing clinical research. In addition, one exciting development from 2012 that appears perhaps particularly beneficial for patients with squamous NSCLC is anti-PD1 antibody immunotherapy, an agent now known as nivolumab.
Here are the video and audio versions of the podcast for this portion of the webinar, along with the associated figures:
[powerpress]
Leighl Highlights in LC 2012 Pt 4 Squam and Anti-PD1 Audio Podcast
Leighl Highlights in LC 2012 Pt 4 Squam and Anti-PD1 Figures
The last portion of her presentation, covering developments in maintenance therapy for advanced NSCLC, will be posted shortly.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: